Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: World J Urol. 2019 Jun 7;38(4):949–956. doi: 10.1007/s00345-019-02835-2

Table 2.

Histology outcomes and perioperative complications of MRI/TRUS fusion prostate biopsy.

Variable One-Stop Pathway(n=74)
 Standard Pathway (n=296)
  
Median (IQR) or n (%) Median (IQR) or n (%) p value
Number of cores biopsy 14 (13–16) 14 (14–16) 0.40
Biopsy histology
     Negative for PCa 29 (39) 142 (48) 0.71
     Positive for PCa 45 (61) 154 (52) 0.19
        Positive for csPCa 30 (41) 101 (34) 0.34
     Grade Group
        1 15 (20) 53 (18)
        2 14 (19) 53 (18)
        3 5 (7) 24 (8) 0.71
        4 7 (9.5) 15 (5)
        5 4 (5.5) 9 (3)
Complication, n % 3 (4) 7 (2) 0.24
     Urinary tract infection 1 3
     Sepsis 1 1
     Urinary retention 0 2
     Rectal bleeding* 1 1

PCa, prostate cancer; csPCa, clinically significant PCa

*

Prolonged bleeding during biopsy requiring local compression.